{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:36:27Z","timestamp":1786116987641,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BSAC OPAT"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Poor aqueous stability limits the use of continuous infusion of intravenous (IV) amoxicillin in outpatient parenteral antimicrobial therapy. This study aimed to evaluate whether buffering improves amoxicillin stability and whether co-administration of probenecid enhances amoxicillin exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Amoxicillin solutions (4.17, 50, and 66.6\u2005mg\/mL) were prepared in 0.3% citrate-buffered saline (pH 7), water for injection, and 0.9% w\/v saline, then stored at 2\u20138\u00b0C for 10\u2005days, followed by 24\u2005h at 32\u00b0C. Stability was assessed using a validated assay method and tested against the UK Yellow Cover Document (YCD) acceptance criteria. A population pharmacokinetic model was developed and used to perform Monte Carlo dosing simulations to evaluate the PTA (95% time above MIC) for various IV amoxicillin regimens, with and without probenecid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Citrate buffering did not improve the stability of amoxicillin, and none of the tested conditions met YCD criteria. Co-administration of probenecid significantly increased the PTA for amoxicillin. Administration of 3\u20136\u2005g of IV amoxicillin every 12\u2005h, with 1\u2005g of probenecid once daily, achieved \u226590% PTA against pathogens with MICs up to 4\u20138\u2005mg\/L depending on infusion durations. For MICs up to 16\u2005mg\/L, 4\u20136\u2005g of IV amoxicillin every 12\u2005h plus 2\u2005g of probenecid once daily achieved a favourable PTA (&amp;gt;90%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Amoxicillin\u2019s aqueous instability was not resolved by citrate buffering. However, for patients requiring IV therapy, probenecid-boosted intermittent and extended infusion regimens of amoxicillin appear to be promising alternatives that warrant further clinical investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag165","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:18:18Z","timestamp":1785237498000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimizing intravenous amoxicillin for outpatient parenteral antimicrobial therapy"],"prefix":"10.1093","volume":"8","author":[{"given":"Zenaw T","family":"Wolie","sequence":"first","affiliation":[{"name":"Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland , Brisbane, Queensland ,","place":["Australia"]},{"name":"Department of Pharmacy, College of Medicine and Health Sciences, Debre Markos University , Debre Markos ,","place":["Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Roberts","sequence":"additional","affiliation":[{"name":"Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland , Brisbane, Queensland ,","place":["Australia"]},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health , Brisbane, Queensland ,","place":["Australia"]},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women\u2019s Hospital , Brisbane, Queensland ,","place":["Australia"]},{"name":"UR UM 103, University of Montpellier, Division of Anesthesia Critical Care and Emergency and Pain Medicine, Nimes University Hospital , Nimes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-9854","authenticated-orcid":false,"given":"Steven C","family":"Wallis","sequence":"additional","affiliation":[{"name":"Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland , Brisbane, Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getnet M","family":"Assefa","sequence":"additional","affiliation":[{"name":"Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland , Brisbane, Queensland ,","place":["Australia"]},{"name":"Department of Pharmacy, College of Medicine and Health Sciences, Wollo University , Dessie ,","place":["Ethiopia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Andrew","family":"Seaton","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital , Glasgow ,","place":["UK"]},{"name":"OPAT Initiative, British Society for Antimicrobial Chemotherapy (BSAC) , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0625-3535","authenticated-orcid":false,"given":"Mark","family":"Gilchrist","sequence":"additional","affiliation":[{"name":"OPAT Initiative, British Society for Antimicrobial Chemotherapy (BSAC) , Birmingham ,","place":["UK"]},{"name":"Department of Pharmacy\/Infection, Imperial College Healthcare NHS Trust , London ,","place":["UK"]},{"name":"Department of Infectious Diseases, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4061-2063","authenticated-orcid":false,"given":"Fekade B","family":"Sime","sequence":"additional","affiliation":[{"name":"Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland , Brisbane, Queensland ,","place":["Australia"]},{"name":"School of Pharmacy and Pharmaceutical Sciences, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland , Brisbane, Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026080608544815500_dlag165-B1","author":"Tackling"},{"key":"2026080608544815500_dlag165-B2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080608544815500_dlag165-B3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2334-14-140","article-title":"Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review","volume":"14","author":"Al-Omari","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2026080608544815500_dlag165-B4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/cid\/ciad168","article-title":"Attainment of target antibiotic levels by oral treatment of left-sided infective endocarditis: a POET substudy","volume":"77","author":"Bock","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026080608544815500_dlag165-B5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jac\/dkad005","article-title":"A systematic review of optimal pharmacokinetic\/pharmacodynamic parameters for beta-lactam therapy in infective endocarditis","volume":"78","author":"Robson","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026080608544815500_dlag165-B6","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/jac\/dkaf144","article-title":"Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach","volume":"80","author":"Dalla Rosa","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026080608544815500_dlag165-B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033540","article-title":"Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomised controlled trials","volume":"10","author":"Lemaignen","year":"2020","journal-title":"BMJ Open"},{"key":"2026080608544815500_dlag165-B8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/clpt.1985.166","article-title":"Dose-dependent absorption of amoxycillin and bacampicillin","volume":"38","author":"Sj\u00f6vall","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"2026080608544815500_dlag165-B9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/nejmoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080608544815500_dlag165-B10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1691\/ph.2011.1023","article-title":"Stability of amoxicillin in portable pumps is drug concentration dependent","volume":"66","author":"Arlicot","year":"2011","journal-title":"Pharmazie"},{"key":"2026080608544815500_dlag165-B11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1179\/1973947815y.0000000052","article-title":"Stability of amoxicillin and amoxicillin\/clavulanic acid reconstituted in isotonic saline","volume":"29","author":"Carlier","year":"2017","journal-title":"J Chemother"},{"key":"2026080608544815500_dlag165-B12","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1093\/ajhp\/43.12.3027","article-title":"Stability of aqueous solutions of amoxicillin sodium in the frozen and liquid states","volume":"43","author":"Concannon","year":"1986","journal-title":"Am J Hosp Pharm"},{"key":"2026080608544815500_dlag165-B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2146\/ajhp130717","article-title":"Stability of ampicillin and amoxicillin in peritoneal dialysis solutions","volume":"72","author":"Patel","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"2026080608544815500_dlag165-B14","first-page":"70","article-title":"Stability of beta-lactamase inhibitors and beta-lactam antibiotics in parenteral formulations as well as in body fluids and tissue homogenates. Comparison of sulbactam, clavulanic acid, ampicillin and amoxicillin","volume":"41","author":"Wildfeuer","year":"1991","journal-title":"Arzneimittelforschung"},{"key":"2026080608544815500_dlag165-B15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/ejhpharm-2021-002937","article-title":"Widening the net: a literature review of antimicrobial agents with potential suitability for outpatient parenteral antimicrobial therapy services\u2014the importance of storage and stability","volume":"30","author":"Jenkins","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"2026080608544815500_dlag165-B16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1128\/aac.17.5.847","article-title":"Effect of orally administered probenecid on the pharmacokinetics of cefoxitin","volume":"17","author":"Vlasses","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"2026080608544815500_dlag165-B17","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.clinthera.2016.06.015","article-title":"Pharmacokinetic and pharmacodynamic principles of anti-infective dosing","volume":"38","author":"Onufrak","year":"2016","journal-title":"Clin Ther"},{"key":"2026080608544815500_dlag165-B18","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.3390\/jcm14082722","article-title":"Antibiotic stability and feasibility in elastomeric infusion devices for OPAT: a review of current evidence","volume":"14","author":"Moreal","year":"2025","journal-title":"J Clin Med"},{"key":"2026080608544815500_dlag165-B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221391","article-title":"Overcoming stability challenges during continuous intravenous administration of high-dose amoxicillin using portable elastomeric pumps","volume":"14","author":"Binson","year":"2019","journal-title":"PLoS One"},{"key":"2026080608544815500_dlag165-B20","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/ajhp\/zxac122","article-title":"Antibiotic stability in portable elastomeric infusion devices: a systematic review","volume":"79","author":"Esteban-Cartelle","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"2026080608544815500_dlag165-B21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.idnow.2022.05.006","article-title":"Probenecid, an old \u03b2-lactams pharmacokinetic enhancer for a renewed use: a retrospective study","volume":"52","author":"Huriez","year":"2022","journal-title":"Infect Dis Now"},{"key":"2026080608544815500_dlag165-B22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/sti.55.3.211","article-title":"Clinical pharmacological studies of amoxycillin: effect of probenecid","volume":"55","author":"Barbhaiya","year":"1979","journal-title":"Br J Vener Dis"},{"key":"2026080608544815500_dlag165-B23","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1093\/jac\/dkx178","article-title":"Adequate plasma drug concentrations suggest that amoxicillin can be administered by continuous infusion using elastomeric pumps","volume":"72","author":"Arensdorff","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026080608544815500_dlag165-B24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2710.1982.tb01029.x","article-title":"The stability of amoxycillin sodium in intravenous infusion fluids","volume":"7","author":"Cook","year":"1982","journal-title":"J Clin Hosp Pharm"},{"key":"2026080608544815500_dlag165-B25","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.2147\/dddt.s474850","article-title":"An evaluation of amoxicillin\/clavulanate stability in aqueous systems, including its suitability for outpatient parenteral antimicrobial therapy (OPAT)","volume":"18","author":"Kamalpersad","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"2026080608544815500_dlag165-B26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/antibiotics14050466","article-title":"Stability of nine time-dependent antibiotics for outpatient parenteral antimicrobial therapy (OPAT) use","volume":"14","author":"d\u2019Huart","year":"2025","journal-title":"Antibiotics"},{"key":"2026080608544815500_dlag165-B27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/jac\/13.6.629","article-title":"The effect of probenecid on serum amoxycillin concentrations up to 18\u2005hours after a single 3\u2005g oral dose of amoxycillin: possible implications for preventing endocarditis","volume":"13","author":"Shanson","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"2026080608544815500_dlag165-B28","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1093\/jac\/dkac200","article-title":"Addition of probenecid to oral \u03b2-lactam antibiotics: a systematic review and meta-analysis","volume":"77","author":"Wilson","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026080608544815500_dlag165-B29","doi-asserted-by":"publisher","first-page":"106161","DOI":"10.1016\/j.jinf.2024.106161","article-title":"No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia","volume":"88","author":"Wei","year":"2024","journal-title":"J Infect"},{"key":"2026080608544815500_dlag165-B30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/antibiotics9070418","article-title":"Narrow-spectrum antibacterial agents\u2014benefits and challenges","volume":"9","author":"Alm","year":"2020","journal-title":"Antibiotics"},{"key":"2026080608544815500_dlag165-B31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s40506-020-00217-6","article-title":"Evaluation of OPAT in the age of antimicrobial stewardship","volume":"12","author":"Mahoney","year":"2020","journal-title":"Curr Treat Options Infect Dis"},{"key":"2026080608544815500_dlag165-B32","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/jac\/dku517","article-title":"Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklists","volume":"70","author":"Gilchrist","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026080608544815500_dlag165-B33","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/antibiotics13100970","article-title":"Enhancing stability and investigating target attainment of benzylpenicillin in outpatient parenteral antimicrobial therapy: insights from in vitro and in vivo evaluations","volume":"13","author":"Rentsch","year":"2024","journal-title":"Antibiotics"},{"key":"2026080608544815500_dlag165-B34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/j.2055-2335.2014.tb00012.x","article-title":"Stability of buffered benzylpenicillin solutions for outpatient parenteral antimicrobial therapy","volume":"44","author":"McDougall","year":"2014","journal-title":"J Pharm Pract Res"},{"key":"2026080608544815500_dlag165-B35","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3390\/pharmaceutics15082099","article-title":"Ampicillin stability in a portable elastomeric infusion pump: a step forward in outpatient parenteral antimicrobial therapy","volume":"15","author":"Rodr\u00edguez-Mart\u00ednez","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026080608544815500_dlag165-B36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/archinte.1955.00250070099012","article-title":"PROBENECID (BENEMID): its uses and side-effects in 2,502 patients","volume":"95","author":"Boger","year":"1955","journal-title":"AMA Arch Intern Med"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag165\/70507090\/dlag165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag165\/70507090\/dlag165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:54:54Z","timestamp":1786020894000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag165\/8753161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag165","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dlag165"}}